

Policy Under Review

Please note that this policy is under review. It does, however, remain current Trust policy subject to any recent legislative changes, national policy instruction (NHS or Department of Health), or Trust Board decision. For guidance, please contact the Author/Owner.

Information Category	Detailed Information
Document Title:	Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults Clinical Guideline V4.0
This document replaces (exact title of previous version):	Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults Clinical Guideline V3.0
Date Issued / Approved:	November 2022
Date Valid From:	December 2022
Date Valid To:	March 2026
Author / Owner:	Dr Keith Mitchell, Consultant Anaesthetist
Contact details:	01872 253392
Brief summary of contents:	This document outlines the potential and actual use of Local Anaesthetic with in RCHT and the precautions and care required
Suggested Keywords:	Pain buster, Nerve infusion, Nerve Block, Local Anaesthesia, Bupivacaine.
Target Audience:	RCHT: Yes CFT: No CIOS ICB: No
Executive Director responsible for Policy:	Chief Medical Officer
Approval route for consultation and ratification:	Anaesthetic Department
Manager confirming approval processes:	Doug Riley

Information Category	Detailed Information
Name of Governance Lead confirming consultation and ratification:	Suzanne Barber
Links to key external standards:	AAGBI Royal College of Anaesthetists. ESRA British Pain Society.
Related Documents:	None
Training Need Identified:	No
Publication Location (refer to Policy on Policies – Approvals and Ratification):	Internet and Intranet
Document Library Folder/Sub Folder:	Clinical/Anaesthesia

This document is only valid on the day of printing.

Controlled Document.

This document has been created following the Royal Cornwall Hospitals NHS Trust Policy on Document Production. It should not be altered in any way without the express permission of the author or their Line Manager.

Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults

V4.0

December 2022

1. Aim/Purpose of this Guideline

- 1.1. Effective analgesia is crucial to patient outcome after major surgery to ensure comfort, mobilisation and decreased risk of potential post-operative complications such as DVT and chest infection.
- 1.2. As surgical techniques change and length of inpatient stay decreases, it is important to offer a safe, flexible method of analgesia which may be delivered in both a hospital and community environment if necessary.
- 1.3. Blockade of pain impulses by local anaesthetic has been shown to give effective pain relief and to decrease other methods of analgesia required – eg opioids with consequent decrease of side effects.
- 1.4. This document outlines the potential and actual use of Local Anaesthetic within RCHT and the precautions and care required.
- 1.5. Purpose:
 - 1.5.1. To ensure that there is a common understanding of use of local anaesthetic to ensure safe delivery of care by all health professionals involved in the care of post-operative patients.
 - 1.5.2. To ensure that the necessary knowledge and competencies are practised throughout the Trust for delivery and care of the patient, knowledge of the drugs, potential side effects and use of any equipment delivering infusions.
 - 1.5.3. To ensure that appropriate training in line with RCHT policies should be undertaken by those using the equipment or delivering bolus injections.
 - 1.5.4. This version supersedes any previous versions of this document.

Data Protection Act 2018 (General Data Protection Regulation – GDPR) Legislation

The Trust has a duty under the Data Protection Act 2018 and General Data Protection Regulations 2016/679 to ensure that there is a valid legal basis to process personal and sensitive data. The legal basis for processing must be identified and documented before the processing begins. In many cases we may need consent; this must be explicit, informed, and documented. We cannot rely on opt out, it must be opt in.

Data Protection Act 2018 and General Data Protection Regulations 2016/679 is applicable to all staff; this includes those working as contractors and providers of services.

For more information about your obligations under the Data Protection Act 2018 and General Data Protection Regulations 2016/679 please see the Information Use Framework Policy or contact the Information Governance Team

Royal Cornwall Hospital Trust rch-tr.infogov@nhs.net

2. The Guidance

2.1. Roles and Responsibilities

2.1.1. Medical_Staff

2.1.1.1. Local anaesthetic blocks are usually delivered by medical staff competent in the technique of nerve blockade either as a single injection or catheter placement for continuous infusion.

2.1.1.2. It would be expected that they have the appropriate knowledge of full aseptic technique, intravenous cannulation and resuscitation skills as per RCHT guidelines, as well as knowledge of the relevant anatomy and the drugs being used, together with treatment of side effects.

2.1.2. Medical Prescribers

2.1.2.1. Should be able to prescribe clearly in line with guidelines stating:

- the total dosage in mg/24 hours
- the volume
- the concentration to be delivered together with
- administration times e.g. hourly or as a timed bolus dose.

2.1.2.2. BNF dosing for Levobupivacaine can be summarized as:

Bolus: 2 mg/kg. Maximum 150mg

Cumulative dose: Maximum 400mg/day

To avoid excessive dosage in obese patients, dose should be calculated on the basis of ideal body-weight.

2.1.2.3. Prescribing teams should review all prescriptions regularly, together with the pain scores and analgesic needs of the patient.

2.1.3. Nursing Staff

2.1.3.1. Nursing staff should be responsible for the timely delivery of analgesia as prescribed – this may include changing an infusion.

Nursing staff are responsible for the ongoing monitoring of pain scores on rest and movement, motor power and sensation and signs of local anaesthetic toxicity as well as the vital monitoring signs of pulse and respiratory rates, oxygen saturation and BP.

2.1.3.2. Adverse reactions should be reported to the prescriber or doctor on the ward and further instruction on administration received.

2.1.3.3. Nurses should contact the Acute Pain Team for further advice if required bleep 3233 during the working week or the anaesthetist on call out of hours. (1st on call Bleep 2746, Senior Anaesthetic Trainee 3513).

2.1.4. Pharmacists

As part of the regular monitoring, pharmacists should ensure adherence to guidelines with regards to appropriateness, accuracy, safety and clarity of prescribing.

2.2. Definition

2.2.1. A peripheral nerve is one which lies outside of the central neural canal (i.e. excludes epidural and spinal blockade).

2.2.2. A continuous peripheral nerve blockade is achieved by placing a fine catheter close to a nerve or nerve receptors and infusing a solution of local anaesthetic either at an hourly rate or as prescribed bolus doses. The presence of the catheter allows the block to continue for a number of days post-surgery, thereby improving patient analgesia, and lessening the need for more invasive blocks or strong opiates.

2.2.3. Infusion rates will depend on the area being blocked and the expected rate of absorption from that area (depending on vascularity).

2.2.4. More than one nerve may supply an area and therefore this technique usually requires adjunct analgesia to avoid discomfort. Where there is major surgery which requires strong opioids, the total dose and risk of opioid side effects will be less.

2.3. Clinical Indications

Table 1 – Indications for peripheral nerve blockade

- Patients expected to experience pain after surgery
- As an alternative to epidural analgesia
- As part of a multimodal approach to analgesia to decrease opiate requirements, avoid urinary catheterisation and potentiate more rapid mobilisation

2.4. Contraindications

Table 2 – Contraindications for peripheral nerve blockade

- Patient refusal
- Previous adverse effects with local anaesthetics
- Superficial infection at site of potential insertion
- Inadequate knowledge to perform block

- Inadequately experienced ward staff to care for patient post operatively
- Bleeding disorders

2.5. Guidelines for Catheter Insertion

- 2.5.1. Catheters should only be placed adjacent to nerves by experienced practitioners with knowledge of the relevant anatomy and an acceptable method for nerve location - electrical stimulation or ultrasound.
- 2.5.2. The patient should have had prior discussion of the technique and the potential complications of nerve damage and local anaesthetics effects.
- 2.5.3. Catheter insertion and consequent injection of local anaesthetic should be performed in a suitable environment where an aseptic technique can be performed and where there are adequate resuscitation facilities.
- 2.5.4. The choice of the catheter rests with the operator – nerve stimulator/ catheter specific sets are available, but the use of epidural catheters is acceptable.
- 2.5.5. Aseptic technique should include hand washing, sterile gloves, face mask and an appropriate skin cleansing preparation and sterile drapes around the injection site.
- 2.5.6. A trained assistant should be present to help with the trolley preparation, location of nerve and consequent insertion.
- 2.5.7. Where chlorhexidine 0.5% is used drying time should be allowed prior to insertion of any needle or catheter (1-2 minutes).
- 2.5.8. Insertion of catheters may have less associated risks if performed in the awake patient although, many patients prefer to be asleep for the procedure. They should be made aware of the potentially slightly increased risk of detection of neural damage.
- 2.5.9. The catheter should be inserted to a reasonable depth percutaneously prior to being secured to minimise movement – current use of the ‘lock it’ device and covered by a clear dressing allows visibility of insertion site
- 2.5.10. Where long term use is required or placement is in a mobile area tunnelling the catheter superficially may be considered.
- 2.5.11. Operators should be aware of local infection guidelines (including the use of antibiotics in special circumstances)
- 2.5.12. Operators should be aware of potential hazards in respect of insertion and removal in patients on anticoagulants or with impaired clotting.
- 2.5.13. Operators should be aware of the monitoring guidelines and be confident that the ward has adequate staff prior to the commencement of the procedure.

2.6. Prescribing Guidelines

2.6.1. Prior to surgery and the initiation of the infusion the operator will consider the suitability of the patient for specific infusions based on:

- Age and physiology
- Risk versus benefit
- Effectiveness of analgesia with respect to type of surgery
- Specific contraindications

2.6.2. All patients must have iv access maintained for the duration of the infusion and the infusion device and catheter must be clearly labelled 'Local Infusion' and the site to which it is attached.

2.6.3. Infusions should be prepared in a sterile environment or pre prepared where possible.

2.6.4. There are limitations on the drugs and concentrations which should be infused to ensure decreased risk of local anaesthetic toxicity.

2.6.5. All drug infusions should take account of patient weight and the recommended safe dose in mg/Kg as per BNF.

2.6.6. When prescribing the local anaesthetic drug the following information should be provided:

- Name of drug
- Site of catheter where drug is to be infused
- Concentration of solution being infused in % and mg/ml
- Hourly rate or frequency of bolus of required
- Maximum dose not to be exceeded over a 24 hour period – in ml and total no of mg

2.6.7. Currently at RCHT there is 0.125% (i.e. 1.25 mg per ml) 200ml bags of Levobupivacaine available for local anaesthetic infusions.

2.6.8. Sterile 10 ml ampoules of Levobupivacaine are available in concentrations of 0.25% and 0.5% (i.e. 2.5 and 5 mg /ml respectively).

2.6.9. The upper recommended dose of bupivacaine as an initial loading dose is 2 mg/kg (lean body mass). Caution is advised dosing per kg actual body weight in morbid obesity – a pragmatic ceiling loading dose of 180mg is probably sensible in all but the most muscular of patients.

2.6.10. Maintenance doses as hourly rates of infusion should not normally exceed 0.5mg/kg/hr, or 2mg/kg at 4-6 hourly top ups.

2.6.11. BNF recommend a total dose of levobupivacaine per 24 hours period is 400mg.

2.6.12. This equates to:

80 ml/24 hours of 0.5 %	maximum rate	3ml/hr
-------------------------	--------------	--------

160 ml/24 hours of 0.25%	maximum rate	6ml/hr
--------------------------	--------------	--------

240ml/24 hours of 0.167%	maximum rate	10ml/hr
--------------------------	--------------	---------

320ml/24 hours of 0.125%	maximum rate	13.3ml/hr
--------------------------	--------------	-----------

400ml/24 hours of 0.1%	maximum rate	16ml/hr
------------------------	--------------	---------

2.6.13. Dilute solutions are found to be effective for analgesia and concentrations over 0.25% are not usually necessary.

2.6.14. Very large volumes could cause swelling and catheter displacement and leakage in more superficially placed catheters.

2.6.15. Infusion rates should rarely be over 5 ml per hour. If a larger volume is required, the concentration should be decreased accordingly. This may be applicable for fascial plane catheters such as Erector Spinae Plane, Fascia Iliaca, and Serratus Anterior Plane.

2.6.16. For specific operations or conditions, there may be bilateral catheters inserted e.g., rectus sheath blocks for a laparotomy; bilateral mastectomies or hernias, when care should be taken to ensure that the sum of each catheter infusate does not exceed the total hourly recommended amount.

2.6.17. A range of rate of infusion should be prescribed together with the necessary supportive therapy such as oxygen according to the Trust guidelines and potential fluid bolus should hypotension occur.

2.6.18. IV, IM or oral opioids may be simultaneously administered without additional risks in line with RCHT policies for opiate administration.

2.6.19. The pain scores should be 0 or 1 on movement and 0 at rest.

2.6.17. A range of rate of infusion should be prescribed together with the necessary supportive therapy such as oxygen according to the Trust guidelines and potential fluid bolus should hypotension occur.

2.7. Local Anaesthetic infusion Devices

Local anaesthetic can be delivered via a catheter using a variety of devices:

- Specific Infusion Pump with a variety of protocols (for indefinite time period)
- Disposable elastomeric pump with pre-determined infusion rate (for up to 48 hours)
- Bolus dose administration by medical or nursing staff.

2.8. Mc Kinley Local Anaesthetic Infusion pumps

2.8.1. There are specifically labelled McKinley 295 pumps for attachment to nerve catheters

Table 3: These have 3 protocols available, as below

LEVOBUPIVACAINE	Infusion rate	Programmed bolus	Patient-controlled bolus
Simple Infusion: Protocol S	(0.5% : max 3ml/hr) (0.25%: max 6ml/hr) 0.125%: max 13ml/hr	None	none
Plane block catheters: Protocol T 0.125% L- BUPIVACAINE	none	15ml / 3hours	10ml hourly

2.8.2. Local anaesthetics, if prescribed correctly, will rarely cause toxic effects however if there is direct infusion into a vein or the solution is absorbed rapidly or a patient is unduly sensitive then the signs and symptoms of toxicity may occur.

2.8.3. Signs are classified as per NEWS chart with relevant treatment guide.

2.8.4. All staff working with local anaesthetic infusions should be aware of the signs and treatments of LA toxicity. If not acted upon in the early stages then respiratory and cardiac arrest can occur which is very difficult to reverse because the 'acidotic' arrest state causes more of the drug to enter the cells and worsen the situation.

2.8.5. Whilst treating the signs and symptoms symptomatically there are also directions for Intralipid Infusion treatment if the condition deteriorates.

2.8.6. All sites where local anaesthetics are used should have an Intralipid Rescue Pack and all staff involved in the care of local anaesthetic infusions should have knowledge of the location and use of the pack.

2.8.7. The infusion rate should be regularly checked and compared with the prescription to ensure correct rate is running and the site of infusion checked for leakage.

Table 4. Signs and symptoms of Local anaesthetic Toxicity (as shown on the NEWS chart)

score	signs	action
0	normal	observe
1	Lightheadedness, lip tingling Tinnitus or metallic taste in mouth	Stop LA infusion, Attach ECG monitor Maintain oxygenation and BP If symptoms deteriorate call for help
2	Visual disturbance Muscle twitching, convulsions	Stop LA infusion, Attach ECG monitor Maintain oxygenation and BP Call for help, give fluids for hypotension Treat convulsions with diazepam
3	Cardiac arrhythmias, hypotension Respiratory and cardiac arrest	As above and treat cardiac arrest with chest compressions and advanced life support. Treat toxicity with Intralipid protocol

2.8.8. Oxygen should be given immediately, and supportive treatment commenced with fluid.

2.8.9. Call for medical help and if severe the intralipid protocol should be commenced

Table 5. Intralipid Rescue

2.8.10. Treatment of cardiac arrest with intralipid 20% emulsion: (approximate doses are given in red for a 70-kg patient)

- Give an intravenous bolus injection of Intralipid® 20% 1.5 ml/kg over 1 min
 - Give a bolus of 100 ml
- Continue CPR
- Start an intravenous infusion of Intralipid® 20% at 15mg/kg/hr
 - Give at a rate of 1000mls/hr

- Repeat the bolus injection twice at 5 min intervals if an adequate circulation has not been restored
 - Give two further boluses of 100 ml at 5 min intervals
- After another 5 min, increase the rate to 30mg/kg/hr if an adequate circulation has not been restored
 - Give at a rate of 2000mls/hr
- Continue infusion until a stable and adequate circulation has been restored
 - Total dose 12ml/Kg – 840ml. (Ref: AAGBI 2010)

Table 6. Cardiac Arrest Treatment with Intralipid - Dose per Kg

Intralipid 20%	1.5ml/Kg over 1 minute
Immediate follow up infusion	15ml/kg/min
Continue chest compression to circulate lipid	
Repeat bolus every 3-5 mins	total dose: 3ml/kg
Continue infusion until haemodynamic stability restored	Increase rate to 30ml/kg if hypotension or unstable
Maximum total daily dose	12ml/kg

2.9. Observations and Monitoring

All patients receiving an infusion of local anaesthetic should be monitored for sensation, motor power and signs of toxicity and the observations recorded with other vital signs on the NEWS chart.

2.9.1. General Observations

2.9.1.1. Nursing staff must be aware of the potential side effects and complications of local anaesthesia and their management. It is assumed that nurses with training for care of epidurals and knowledge of the side effects and potential signs of toxicity will be able to care for patients with local infusions.

2.9.1.2. Timely observations are necessary for the safe delivery of this method of analgesia.

2.9.1.3. All observations will be recorded on the RCHT NEWS chart which combines the regular observations of vital functions (RR, BP, HR, oxygen saturation and urine output) with those more specific parameters and scores necessary for safe and effective local analgesia delivery:

Pain at rest and movement, sedation, sensation, power and signs of LA toxicity.

2.9.1.4. Scoring criteria are at the bottom of the NEWS observation chart and those scores within red area would indicate that there are potential side effects occurring and the algorithms on the reverse of the form should be referred to.

2.9.1.5. Observations should be more frequent in the first 6 hours or if the rate of infusion is changed – frequency of observations required are on the reverse of the NEWS chart.

2.9.1.6. The rate of infusion should be recorded with every observation.

2.9.1.7. General observations when local anaesthetic technique is not accompanied by strong opiates.

Table 7. Necessary frequency of observations

Monitoring parameter	1 st hour	Following 2 hours	thereafter
Respiratory Rate	Every 15 mins	hourly	4 Hourly for 24 hrs
Blood Pressure	Every 15 mins		
Heart Rate/sats	Every 15 mins		
Pain score at rest	Every 15 mins	Hourly	4 Hourly for 24 hrs
Pain score on movement	Every 15 mins	hourly	4 Hourly for 24 hrs
Sedation	Every 15 mins		4 Hourly for 24 hrs
Motor power	once	2 hourly	4 Hourly for 24 hrs
sensation	With pain scores		
LA toxicity	hourly	2 hourly	4 Hourly

*If patient is stable and infusion rate remains unchanged monitor 4 hourly after this, if patient is in pain, the rate of infusion changes or the patient is in labile condition the continue with observations more frequently.

2.9.2. Respiratory Rate

2.9.2.1. Regular monitoring of the respiratory rate should accompany the monitoring of the use of local anaesthetic particularly if it is being used in conjunction with strong opiates e.g. with a PCA as a multimodal approach when observations should be as for those patients with a PCA and epidural infusions.

Table 8. Necessary frequency of observations with LA infusion and parenteral opiates.

Monitoring parameter	1 st hour	Following 2 hours	thereafter
Respiratory Rate	Every 15 mins	Every 30 mins	Hourly for 24 hrs
Blood Pressure	Every 15 mins	Every 30 mins	Hourly for 12 hrs, then 4 hourly if stable
Heart Rate/sats	Every 15 mins	Every 30 mins	Hourly for 12 hrs then 4 hourly if stable
Pain score at rest	Every 15 mins	Every 30 mins	Hourly for 24 hrs
Pain score on movement	Every 15 mins	Every 30 mins	Hourly for 24 hrs
Sedation	Every 15 mins	Every 30 mins	Hourly for 24 hrs
Motor power	once	*Every hr	4 hourly for 24 hrs
sensation	With pain scores		
LA toxicity	hourly	2 hourly	Hourly for 24 hrs

2.9.2.2. If respiratory rate falls below 8 when local analgesia is used in conjunction with a PCA, give oxygen and follow algorithm on NEWS chart.

2.9.2.3. The decrease in respiratory rate is more likely to be due to the opiates if no other signs of toxicity are detected and the PCA should be temporarily stopped and observations increased.

Table 9. Recommended action for decreased respiratory rate with LA infusion and PCA.

Resp Rate	Action to take
≤ 10	Increase frequency of Observations
≤ 8	Stop PCA infusion, give oxygen, observe and consider naloxone
≤ 5	As above and give naloxone immediately and stop LA infusions

Table 10 – Naloxone mixture

<p>400microgms of Naloxone should be diluted in 3ml of 0.9%NaCl</p> <p>Give in 1 ml increments every 5 mins</p> <p>Give until resp rate increases to 8 and sedation score greater than 2</p> <p>Seek medical advice if resp rate remains low</p>
--

2.9.3. Management of hypotension

- 2.9.3.1. Sympathetic blockade by local anaesthetic can sometimes occur, particularly when catheter is in close proximity to sympathetic nerves or is causing vasodilation
- 2.9.3.2. Other causes for decrease in blood pressure should be excluded before assuming they are due to the local infusion.
- 2.9.3.3. Systolic blood pressure should be greater than 90mmHg systolic unless otherwise stated. Hypertensive patients may require a higher baseline to maintain organ function – particularly urine output. It would be expected that the anaesthetist involved in the catheter insertion would state acceptable parameters for systolic pressure (level and time period) after which intervention would be required in terms of fluid bolus as per chart.

Table11. Recommended Action for hypotension

Consciousness/saturation	action
Alert	Lie patient flat
Normal saturation	<p>Give oxygen 8 litre/min</p> <p>Give plasma expander – 250ml of crystalloid</p> <p>Do not put patient head down only if LA infusion</p>

Consciousness/saturation	action
	above waist.
Drowsy Saturation less than 92%	Lie patient flat Do not put head down if LA infusion above waist Give oxygen Give plasma expander – up to 500ml Call for medical help Give ephedrine 3-9mg iv

2.9.3.4. Following the administration of a bolus dose of fluid the blood pressure must be observed at 5 min intervals until increasing or for 30 mins after stable.

2.9.4. Heart Rate

- If there is a bradycardia with normal BP check level at which patient is numb
- Call for medical help if rate 10-20 below normal base rate
- Administer either ephedrine (to increase pulse and BP) 3- 6 mg bolus or
- Give Atropine 600micrograms for persistent bradycardia
- If heart rate falls below 40/min or patient is compromised put out urgent response bleep or crash call.

2.9.5. Pain Score and sensation

2.9.5.1. Pain scores and sensation should be recorded and documented regularly with every observation when patient is awake – both at rest and on movement. If patient is asleep then this may be recorded but not for more than 3 successive observations.

2.9.5.2. If pain score is higher than 1 adjust rate of infusion to maximum, ensure multimodal analgesia is given and if pain continues contact medical staff for advice

2.9.5.3. N.B. Strong opiates may be given with LA infusions

2.9.6. Sedation

If Sedation score is greater than 2 then medical help should be sought.

2.9.7. Nausea Score

Patients should be regularly checked for feelings of nausea and vomiting and all should have appropriate anti emetics prescribed as per RCHT guidelines.

2.10. Catheter Management

2.10.1. Catheter Site Care

- 2.10.1.1. Catheters are not sutured in place and therefore may easily fall out.
- 2.10.1.2. Dressing changes to the catheter exit site should only be carried out by the Acute Pain team or an anaesthetist when it is necessary.
- 2.10.1.3. The aims are to ensure sterility and security of the system and prevent entry of bacteria into the potential space and allow visibility of the catheter.
- 2.10.1.4. If changing the dressing all sterile precautions should be taken in accordance with RCHT policy.
- 2.10.1.5. The catheter is fixed with a 'lockit clip'; removal of this clip would necessitate disconnection of the catheter and its threading through the lock it port – this should only be undertaken by trained acute pain nurses and anaesthetists as there is a high risk of catheter dislodgement.
- 2.10.1.6. The dressing should be smooth and there should be no kinks in the catheter.
- 2.10.1.7. It is the nurses' responsibility to check the catheter site regularly (e.g. twice daily) to check that the dressing is secure and remains covering the catheter.
- 2.10.1.8. If the dressing is insecure or there is a leak of fluid, it should be secured with additional tape and pad.

2.10.2. Catheter Line and Filter

- 2.10.2.1. Nursing management of the line and filter should aim to prevent disconnection of the filter from the catheter and maintain the integrity of the system as well as promoting comfort at the filter site.
- 2.10.2.2. Effective management of the catheter line is essential in preventing any pulling of the actual catheter and its potential dislodgement or disconnection.
- 2.10.2.3. If the catheter becomes disconnected or dislodged it should not usually be replaced and will usually require removal which can be undertaken by any competent health professional trained in

aseptic technique. (see removal) If there is reluctance to remove the catheter and further advice is needed:

- Wrap the filter and catheter in gauze
- Stop the infusion
- Contact the acute pain team or the anaesthetist on call.

2.10.3. Removal of Catheters

- 2.10.3.1. Local anaesthetic infusion catheters can be removed by registered nurses who have been trained and assessed as competent in aseptic technique.
- 2.10.3.2. The catheter should be removed taking into consideration the timing of any prophylactic anticoagulation (see section 2.12). Catheter removal early in the day will ensure sufficient time to monitor patient during working hours for any signs of haematoma at the site of entry and exit.
- 2.10.3.3. Catheter removal should not routinely occur unless the patient's clotting is normal or within an accepted range - INR \leq 1.5 and a platelet count of \geq 80/nl.
- 2.10.3.4. It would be expected that if the bleeding history is negative that routine coagulation screening prior to removal would not be required. (FBC prior to surgery to confirm platelet count would be acceptable).
- 2.10.3.5. Catheters have not been fixed within the space and once the 'lock-it' is removed the catheter should be freed with minimal pressure.
- 2.10.3.6. If the catheter feels as if there is some resistance do not force and contact the acute pain team or the anaesthetist on call for advice.
- 2.10.3.7. Check the catheter after removal to ensure the entire length has been removed and that a rounded tip is present.

Procedure for Removal of Catheter:

- Wash hands as per RCHT hand hygiene policy
- Gather equipment – a small dressing and gloves
- Explain the procedure to the patient
- Position the patient comfortably where access to the catheter is easiest
- Remove the catheter slowly

- Observe the site for leakage, fluid or signs of infection.
- Check catheter to ensure tip is complete – if not contact Acute Pain Team for advice.
- Clean with NaCl 0.9% and apply adhesive dressing over site
- Check for any signs of infection such as pus or redness at site of entry – if there are any signs save the catheter tip for Culture and sensitivity and swab the insertion site.

2.11. Anticoagulants and Local Infusion Catheters

Consideration must be paid to the patients' anticoagulation status prior to catheter removal and should be in line with RCHT anticoagulation/DVT prophylaxis policy.

The Association of Anaesthetists of Great Britain and Ireland and Regional Anaesthesia UK have produced a very useful consensus guideline on this topic (https://www.aagbi.org/sites/default/files/rapac_2013_web.pdf), on which the below guidance is based. It ranks catheter sites in order of risk, as well as giving specific timings for all the currently available anticoagulants.

Risk of thrombosis due to withheld anticoagulants versus risk of haematoma at catheter insertion/withdrawal site should be considered. For low-risk sites (eg wound-site infusions and fascial plane blocks) in high risk patients (eg mechanical heart valve, recent PE), continuing treatment doses and removing catheter in a relatively low risk period (eg 18-20 hours after last dose and 4-6 hours prior to next due dose) may represent the overall lowest risk strategy. Involvement of senior decision makers and documentation of rationale is advised in such cases.

It is unlikely that removal of catheter will cause bleeding and if this is the case then local pressure should be applied for 5 minutes or until it has decreased.

Specific advice for common anticoagulants follows.

2.11.1. IV Heparin

- 2.11.1.1. There may be increased incidence of haematoma if patient is receiving iv heparin particularly if the therapeutic ratio is $\geq 2 - 2.5$.
- 2.11.1.2. Catheters placed prior to heparin administration should not present a problem
- 2.11.1.3. If the patient remains on heparin and it is considered essential to place a catheter for LA infusion then Heparin should be stopped 2-4 hours pre procedure (insertion and removal) and checking an urgent APTT ratio 2 hours prior to procedure.
- 2.11.1.4. If required the IV heparin infusion can be restarted at least 1 hour after catheter insertion.

2.11.1.5. Patients receiving peri operative heparinisation, such as those undergoing vascular surgery, should have the insertion of catheter prior to heparinisation, and not have the catheter removed for at least 12hours post operatively after a coagulation check is normal.

2.11.2. Dalteparin

2.11.2.1. Careful consideration as to the need for indwelling LA infusions should occur prior to this method of analgesia being selected when the following precautions are suggested should be taken:

2.11.2.2. Prophylactic dose (eg 5000u s/c):

- Wait 6 hours after catheter insertion / removal before administering;
- Wait 12 hours after administering before inserting/removing catheter.

This gives a 6 hour window for removal if administration times are to be unchanged (eg for 22:00 dosing, removal window 10:00-16:00).

Treatment dose (eg 100units/kg sc):

- Wait 6 hours after catheter insertion / removal before administering.
- Wait 24 hours after administering before catheter insertion/removal.
- Following both the above timings will necessitate a ≥ 6 hour extra wait between doses (total ≥ 30 hour interval between two doses).

If the patient has received a larger dose then avoid regional techniques.

2.11.3. Warfarin

2.11.3.1. Ideally the INR should be < 1.5 before catheter is inserted or removed but consider risk/benefit of stopping anticoagulant therapy. Involvement of senior decision makers and documentation of rationale is advised.

2.11.3.2. If a local infusion catheter inadvertently falls/is removed whilst a patient is anti coagulated there may be an increased risk of haematoma and a pressure dressing to the area should be applied.

2.12. Discontinuing local anaesthetic infusion.

Removal of catheter usually occurs after 72 hours. The risk of infection increases after with time.

This risk may increase in immunocompromised and diabetic patients.

There may be occasions when there needs to be more prolonged analgesia. The catheter could stay in situ provided there is no leakage or sign of inflammation.

Anticipated long term LA analgesia should have a tunneled catheter inserted and advice of the acute pain team or pain consultants may be needed.

Factors to Consider Prior to Discontinuation

2.12.1. Severity of pain expected.

- Patient's ability to tolerate other routes of analgesia.
- It would be anticipated that this has been part of a multimodal analgesic approach therefore other analgesia has probably been administered, however if this is not the case, then analgesia must be prescribed before the infusion is stopped. Analgesia should be prescribed as regular as well as prn.
- Regular pain assessment should continue to ensure patient's pain control is well managed

2.12.2. Patient preference.

- Patients or carers wishes should be taken into consideration. If a patient requests that they no longer wish to receive local anaesthetic infusions then alternative options should be discussed ensuring the patient is fully informed prior to making a choice.

3. Monitoring compliance and effectiveness

Information Category	Detail of process and methodology for monitoring compliance
Element to be monitored	Adherence to RCHT guidelines
Lead	Acute pain lead
Tool	Regular audits and regular surveillance will occur throughout the year and reported at the regular acute pain meetings and appropriate governance meetings
Frequency	Yearly audit as required by NPSA guidelines will be undertaken.
Reporting arrangements	The committee reviewing the cases will be the anaesthesia directorate. Cases will be discussed at audit meetings and the details will be recorded in the minutes.
Acting on recommendations and Lead(s)	See above
Change in practice and lessons to be shared	Required changes to practice will be identified and implemented within a month. A lead member of the team will be identified to take each change forward where appropriate. Lessons will be shared with all the relevant stakeholders

4. Equality and Diversity

4.1. This document complies with the Royal Cornwall Hospitals NHS Trust service Equality and Diversity statement which can be found in the '[Equality, Inclusion and Human Rights Policy](#)' or the [Equality and Diversity website](#).

4.2. Equality Impact Assessment

The Initial Equality Impact Assessment Screening Form is at Appendix 2.

Appendix 1. Governance Information

Information Category	Detailed Information
Document Title:	Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults Clinical Guideline V4.0
This document replaces (exact title of previous version):	Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults Clinical Guideline V3.0
Date Issued/Approved:	November 2022
Date Valid From:	December 2022
Date Valid To:	December 2025
Directorate / Department responsible (author/owner):	Dr Keith Mitchell, Consultant Anaesthetist
Contact details:	01872 253392
Brief summary of contents:	This document outlines the potential and actual use of Local Anaesthetic with in RCHT and the precautions and care required
Suggested Keywords:	Pain buster, Nerve infusion, Nerve Block, Local Anaesthesia, Bupivacaine.
Target Audience:	RCHT: Yes CFT: No CIOS ICB: No
Executive Director responsible for Policy:	Chief Medical Officer
Approval route for consultation and ratification:	Anaesthetic Department
General Manager confirming approval processes:	Doug Riley
Name of Governance Lead confirming approval by specialty and care group management meetings:	James Masters
Links to key external standards:	AAGBI Royal College of Anaesthetists ESRA British Pain Society

Information Category	Detailed Information
Related Documents:	None
Training Need Identified?	No
Publication Location (refer to Policy on Policies – Approvals and Ratification):	Internet and Intranet
Document Library Folder/Sub Folder:	Clinical / Anaesthesia

Version Control Table

Date	Version Number	Summary of Changes	Changes Made by
07 Jan 12	V1.0	Initial Issue	Dr Anne Dingwall Consultant Anaesthetist
09 Feb 15	V2.0	Updated guideline. Addition of Monitoring Compliance table.	Dr Juan Graterol Consultant Anesthetist
09 Feb 15	V2.1	Governance information moved to an appendix. EIA updated. Governance information amended to align with format of Document Manager	Dr Juan Graterol Consultant Anesthetist
09 Feb 15	V2.2	Updated governance information table to include KCCG.	Dr Juan Graterol Consultant Anesthetist
July 19	V3.0	Updated, reviewed and new format	Dr Nick Marshall Consultant Anaesthetist
November 2022	V4.0	Updated, reviewed and new format	Dr Keith Mitchell Consultant Anaesthetist

All or part of this document can be released under the Freedom of Information Act 2000

This document is to be retained for 10 years from the date of expiry.

This document is only valid on the day of printing

Controlled Document

This document has been created following the Royal Cornwall Hospitals NHS Trust Policy for the Development and Management of Knowledge, Procedural and Web

Documents (The Policy on Policies). It should not be altered in any way without the express permission of the author or their Line Manager.

UNDER REVIEW

Appendix 2. Equality Impact Assessment

Section 1: Equality Impact Assessment (EIA) Form

The EIA process allows the Trust to identify where a policy or service may have a negative impact on an individual or particular group of people.

For guidance please refer to the Equality Impact Assessment Policy (available from the document library) or contact the Equality, Diversity and Inclusion Team rcht.inclusion@nhs.net

Information Category	Detailed Information
Name of the strategy / policy / proposal / service function to be assessed:	Continuous Local Anaesthetic Infusions for Post-Operative Pain Relief in Adults Clinical Guideline V4.0
Directorate and service area:	Anaesthesia
Is this a new or existing Policy?	Existing
Name of individual completing EIA (Should be completed by an individual with a good understanding of the Service/Policy):	Dr Keith Mitchell, Consultant Anaesthetist
Contact details:	01872 253392

Information Category	Detailed Information
1. Policy Aim - Who is the Policy aimed at? (The Policy is the Strategy, Policy, Proposal or Service Change to be assessed)	To provide guidelines for those caring for a patient with a local anaesthesia nerve infusion. Doctors and Nurses.
2. Policy Objectives	To provide information for the setup and safe use of a local anaesthesia nerve infusion in the ward environment.
3. Policy Intended Outcomes	Safe and appropriate use of local anaesthetic infusions on the ward
4. How will you measure each outcome?	Monitoring through audit and case discussion at governance meetings.
5. Who is intended to benefit from the policy?	Patients

Information Category	Detailed Information
6a. Who did you consult with? (Please select Yes or No for each category)	<ul style="list-style-type: none"> • Workforce: Yes • Patients/ visitors: No • Local groups/ system partners: No • External organisations: No • Other: No
6b. Please list the individuals/groups who have been consulted about this policy.	Anaesthetic Department
6c. What was the outcome of the consultation?	Agreed.
6d. Have you used any of the following to assist your assessment?	National or local statistics, audits, activity reports, process maps, complaints, staff or patient surveys: No

7. The Impact

Following consultation with key groups, has a negative impact been identified for any protected characteristic? Please note that a rationale is required for each one.

Where a negative impact is identified without rationale, the key groups will need to be consulted again.

Protected Characteristic	(Yes or No)	Rationale
Age	No	
Sex (male or female)	No	
Gender reassignment (Transgender, non-binary, gender fluid etc.)	No	
Race	No	
Disability (e.g. physical or cognitive impairment, mental health, long term conditions etc.)	No	
Religion or belief	No	

Protected Characteristic	(Yes or No)	Rationale
Marriage and civil partnership	No	
Pregnancy and maternity	No	
Sexual orientation (e.g. gay, straight, bisexual, lesbian etc.)	No	

A robust rationale must be in place for all protected characteristics. If a negative impact has been identified, please complete section 2. If no negative impact has been identified and if this is not a major service change, you can end the assessment here.

I am confident that section 2 of this EIA does not need completing as there are no highlighted risks of negative impact occurring because of this policy.

Name of person confirming result of initial impact assessment: Dr Keith Mitchell, Consultant Anaesthetist

If a negative impact has been identified above OR this is a major service change, you will need to complete section 2 of the EIA form available here: [Section 2. Full Equality Analysis](#)